CN109078172A - A kind of preparation and its application based on autologous tissue - Google Patents
A kind of preparation and its application based on autologous tissue Download PDFInfo
- Publication number
- CN109078172A CN109078172A CN201810978453.XA CN201810978453A CN109078172A CN 109078172 A CN109078172 A CN 109078172A CN 201810978453 A CN201810978453 A CN 201810978453A CN 109078172 A CN109078172 A CN 109078172A
- Authority
- CN
- China
- Prior art keywords
- autologous
- tissue
- fat
- preparation
- stem cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 61
- 210000000130 stem cell Anatomy 0.000 claims abstract description 56
- 102000008186 Collagen Human genes 0.000 claims abstract description 37
- 108010035532 Collagen Proteins 0.000 claims abstract description 37
- 229920001436 collagen Polymers 0.000 claims abstract description 34
- 230000010261 cell growth Effects 0.000 claims abstract description 8
- 230000001737 promoting effect Effects 0.000 claims abstract description 6
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 5
- 210000004369 blood Anatomy 0.000 claims description 50
- 239000008280 blood Substances 0.000 claims description 50
- 210000001519 tissue Anatomy 0.000 claims description 44
- 210000000577 adipose tissue Anatomy 0.000 claims description 23
- 238000002347 injection Methods 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 17
- 210000003743 erythrocyte Anatomy 0.000 claims description 16
- 238000003860 storage Methods 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 230000001376 precipitating effect Effects 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 238000005119 centrifugation Methods 0.000 claims description 8
- 102000012422 Collagen Type I Human genes 0.000 claims description 7
- 108010022452 Collagen Type I Proteins 0.000 claims description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 210000001015 abdomen Anatomy 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 7
- 238000004587 chromatography analysis Methods 0.000 claims description 7
- 238000011026 diafiltration Methods 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 230000004927 fusion Effects 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 7
- 230000008676 import Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 7
- 239000002504 physiological saline solution Substances 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 239000003643 water by type Substances 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 6
- 210000004872 soft tissue Anatomy 0.000 claims description 6
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 4
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000003431 cross linking reagent Substances 0.000 claims description 4
- 229940116977 epidermal growth factor Drugs 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 102000013275 Somatomedins Human genes 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 210000000481 breast Anatomy 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 8
- 230000004083 survival effect Effects 0.000 abstract description 6
- 208000027418 Wounds and injury Diseases 0.000 abstract description 4
- 230000003416 augmentation Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 230000017074 necrotic cell death Effects 0.000 abstract description 3
- 230000000250 revascularization Effects 0.000 abstract description 3
- 208000005422 Foreign-Body reaction Diseases 0.000 abstract description 2
- 230000024245 cell differentiation Effects 0.000 abstract description 2
- 238000011049 filling Methods 0.000 abstract description 2
- 210000002381 plasma Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 10
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 8
- 238000004321 preservation Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000003328 fibroblastic effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- XEUCQOBUZPQUMQ-UHFFFAOYSA-N Glycolone Chemical compound COC1=C(CC=C(C)C)C(=O)NC2=C1C=CC=C2OC XEUCQOBUZPQUMQ-UHFFFAOYSA-N 0.000 description 1
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/04—Materials or treatment for tissue regeneration for mammary reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of preparation based on autologous tissue, the preparation includes autologous collagen albumen and autologous fat stem cell.The invention also discloses a kind of applications of preparation based on autologous tissue.The embodiment of the present invention is enlarged the bosom using the transplanting that autologous collagen albumen and autologous fat stem cell mediate, autologous fat stem cell can significantly improve the survival rate of transplant fat cell, the tissue of autologous fat stem cell differentiation is combined with autologous collagen albumen, further collocation uses the Porcine HGF for promoting cell growth, the absorption, infection, necrosis of transplant fat can be effectively inhibited, promote the revascularization of transplant fat tissue, transplant fat high survival rate, mammoplasia effect are good.The embodiment of the present invention carries out tissue augmentation using the effective component of autologous tissue, which will not generate foreign body reaction from autologous patient tissue, securely and reliably, has acquisition convenience, abundance, filling effect good and the advantages such as wound is small.
Description
Technical field
The present invention relates to biologic product technology fields, and in particular to a kind of preparation and its application based on autologous tissue.
Background technique
It enlarges the bosom also known as mamaplasty or chest enlarge, is to expand breast volume, shape by implantation medical material or transplanting autologous tissue
State is plentiful well-balanced, a kind of operation for improving women figure, restoring the peculiar beautiful curve of women.From the beginning of the eighties in 19th century, enlarge the bosom elder generation
After experienced atoleine injection augmentation mammaplasty, silicone oil, the implantation of silicone breast etc., but due to its related complication, including contracture,
It deforms, be hardened, leaking, the problems such as feel is unnatural puzzles ask doctor and doctor always.Therefore, find safely, effectively, nothing
Malicious, lasting tissue substitute at development of enlarging the bosom key.
Autologous fat is to draw extra subcutaneous fat cells from the certain positions of human body itself, then the mixing by being sucked out
The purified processing of object, injection of medicine obtain composite fat granule.When it was recognized that autologous fat is likely to become the material of breast augmentation
When material, it is immediately exposed to ask the welcome of doctor and performer, and be assigned to very big expectation.Autologous fat injection is enlarged the bosom, from 19th century
End initially enters clinic, due to its feel is natural, wound is small, it is technology continuously improve maturation, the person of being treated surgically increasingly increases
It is more.However the win or lose that autologous fat injection is enlarged the bosom is related with the survival rate of fat cell, exists after adipose tissue injection and inhales
The problems such as receipts, therefore Repeated Operation is usually needed, and have the complication problems such as liquefaction infection.
In consideration of it, proposing the contents of the present invention.
Summary of the invention
Of the existing technology in order to solve the problems, such as, being designed to provide for the embodiment of the present invention is a kind of based on autologous tissue
Preparation and its application.
To achieve the above object, the first aspect of the embodiment of the present invention provides a kind of preparation based on autologous tissue, described
Preparation includes autologous collagen albumen and autologous fat stem cell.
Further, institute's preparation is injection, and preparation method includes:
Step 1: the preparation of autologous collagen albumen
By blood taking needle, to human body, blood was collected, and blood enters whole blood separator after being centrifuged for the first time, and separates in whole blood
Secondary centrifuging is carried out in device, whole blood centrifugation is divided into three layers, plasma layer, tunica albuginea layer and red blood cell layer is followed successively by from top to bottom, by blood
The liquid of pulp layer, tunica albuginea layer and red blood cell layer, which passes through conduit respectively and imports different storage elements, separately to be stored, by storage element
Appropriate plasma layer and the mixing of tunica albuginea layer liquid proportional are taken out, and further through chromatography unit progress preliminary purification, diafiltration unit
It purifies up to required autologous collagen albumen；
Step 2: the preparation of autologous fat stem cell
(1) fat stem cell separates: obtaining the autologous adipose tissue for being located at abdomen, physiological saline, mixing, with revolving speed is added
1200-1800r/min is centrifuged 10-20min, removes remaining haemocyte and fragment of tissue, adipose tissue is obtained, to the fat
The Type I collagen enzyme solutions that mass concentration is 0.075-0.1% are added in 1:2-3 to tissue by volume, digest in 37 DEG C of waters bath with thermostatic control
30-60min is centrifuged 2-6min with revolving speed 1000-1500r/min, discards upper-layer fat tissue and lower layer's suspension, it is dry to obtain fat
Cell precipitation；
(2) fat stem cell culture: being added DMEM culture medium for the fat stem cell of acquisition precipitating and be resuspended, be placed in 37 DEG C,
5%CO2Culture, passage, when the degrees of fusion of the fat mesenchymal stem cell is up to 80% or more, are collected thin until the 3rd generation terminated
Born of the same parents use or freeze；
Step 3: production preparation
By autologous fat stem cell made from autologous collagen albumen made from step 1 and step 2, it is uniformly mixed, is placed in 4
DEG C Preservation in sterile condition.
Further, the preparation further includes the Porcine HGF for promoting cell growth, according to weight,
The preparation includes autologous collagen albumen 50-80%, autologous fat stem cell 20-50%, the cell growth for promoting cell growth
Factor 10-30%.
Further, the Porcine HGF includes fibroblast growth factor, epidermal growth factor, para-insulin
One of growth factor is a variety of.
Further, the preparation further includes the crosslinking agent that weight percentage is 1-20%.
Further, the crosslinking agent in 1,4- butanediol glycidol ether, two contracting glycerin ether of polyethylene glycol one
Kind or two kinds.
The second aspect of the embodiment of the present invention provides a kind of above-mentioned fill out based on the preparation of autologous tissue preparing soft tissue
Fill the application in agent.
Further, the soft tissue is chest soft tissue.
Breast is made of connective tissue and adipose tissue, and tall and straight plentiful breast largely relies on holding for connective tissue
Support.And collagen is the main component of connective tissue, collagen is often interweaved into polysaccharide protein in connective tissue
Reticular structure generates certain mechanical strength, is support body curve, embodies the material base of tall and straight posture.Fat stem cell tool
There are more differentiation potentials, and genetic stability, is organizational project and the ideal seed cell of regenerative medicine.
The enriched blood platelet and collagen that the autologous collagen albumen of the embodiment of the present invention is extracted by human vein blood
Autologous collagen albumen be made, blood is divided into three layers through centrifugation, and plasma layer mainly includes blood plasma, water, protein, salt and various
Ion etc., tunica albuginea floor mainly include rich in blood platelet area, are rich in lymphocyte area, rich in monocyte area and rich in granulocyte
Area, red blood cell layer can simply be divided into Young erythrocyte and normocyte, contain in the plasma layer and tunica albuginea layer mixed liquor of extraction
A large amount of collagens, while can stimulation collagen, elasticity into after high dermis rich in blood platelet and various growth factors
The generation of fiber, colloid etc., promotes regeneration.
Fat stem cell is isolated a kind of stem cell with multi-lineage potential from adipose tissue, research hair
Existing fat stem cell can stable proliferation and decline rate is low in vitro, while there are materials to be easy for it, a small amount of tissue can obtain
The advantages that a large amount of stem cells are suitable for large-scale culture, small to body injury, and its is from a wealth of sources, and cylinder storage amount is big, is suitable for
The characteristics of autotransplantation.Various kinds of cell growth factor can be secreted during fat stem cell is in growing multiplication simultaneously, such as at fibre
Porcine HGF, keratinocyte growth factor etc. are tieed up, is had and is promoted cell turnover, promotes damaged cell tissue healing, increase thin
The effects of born of the same parents' vigor and skin immunity, beautifying and anti-aging.
The embodiment of the present invention has the advantages that
1, the embodiment of the present invention is enlarged the bosom using the transplanting that autologous collagen albumen and autologous fat stem cell mediate, autologous fat
Stem cell can significantly improve the survival rate of transplant fat cell, the tissue and autologous collagen albumen phase of autologous fat stem cell differentiation
In conjunction with further collocation can effectively inhibit absorption, the sense of transplant fat using the Porcine HGF for promoting cell growth
Dye, necrosis, promote the revascularization of transplant fat tissue, transplant fat high survival rate, mammoplasia effect are good.
2, the embodiment of the present invention using autologous tissue effective component carry out tissue augmentation, the extract from patient from
Body tissue will not generate foreign body reaction, securely and reliably, have and obtain convenience, abundance, filling effect are good and wound is small etc.
Advantage.
Specific embodiment
The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention..
Embodiment 1
The injection based on autologous tissue of the present embodiment, preparation method include:
Step 1: the preparation of autologous collagen albumen
By blood taking needle, to human body, blood was collected, and blood enters whole blood separator after being centrifuged for the first time, and separates in whole blood
Secondary centrifuging is carried out in device, whole blood centrifugation is divided into three layers, plasma layer, tunica albuginea layer and red blood cell layer is followed successively by from top to bottom, by blood
The liquid of pulp layer, tunica albuginea layer and red blood cell layer, which passes through conduit respectively and imports different storage elements, separately to be stored, by storage element
It takes out appropriate plasma layer and tunica albuginea layer liquid is mixed by 1:1, and is further pure through chromatography unit progress preliminary purification, diafiltration unit
Change up to required autologous collagen albumen；
Step 2: the preparation of autologous fat stem cell
(1) fat stem cell separates: obtaining the autologous adipose tissue for being located at abdomen, physiological saline, mixing, with revolving speed is added
1600r/min is centrifuged 15min, removes remaining haemocyte and fragment of tissue, obtains adipose tissue, presses body to the adipose tissue
The Type I collagen enzyme solutions that mass concentration is 0.075% are added than 1:2 for product, 60min are digested in 37 DEG C of waters bath with thermostatic control, with revolving speed
1200r/min is centrifuged 4min, discards upper-layer fat tissue and lower layer's suspension, obtains fat stem cell precipitating；
(2) fat stem cell culture: being added DMEM culture medium for the fat stem cell of acquisition precipitating and be resuspended, be placed in 37 DEG C,
5%CO2Culture, passage, when the degrees of fusion of the fat mesenchymal stem cell is up to 80% or more, are collected thin until the 3rd generation terminated
Born of the same parents use or freeze；
Step 3: production preparation
Weight percentage, by autologous collagen protein 60 %, autologous fat stem cell 25%, fibroblastic growth
The factor 15%, 1,4- butanediol glycidol ether 5% are uniformly mixed, preparation are made, is placed in 4 DEG C of Preservation in sterile condition.
Embodiment 2
A kind of injection based on autologous tissue, preparation method include:
Step 1: the preparation of autologous collagen albumen
By blood taking needle, to human body, blood was collected, and blood enters whole blood separator after being centrifuged for the first time, and separates in whole blood
Secondary centrifuging is carried out in device, whole blood centrifugation is divided into three layers, plasma layer, tunica albuginea layer and red blood cell layer is followed successively by from top to bottom, by blood
The liquid of pulp layer, tunica albuginea layer and red blood cell layer, which passes through conduit respectively and imports different storage elements, separately to be stored, by storage element
It takes out appropriate plasma layer and tunica albuginea layer liquid is mixed by 1:1, and is further pure through chromatography unit progress preliminary purification, diafiltration unit
Change up to required autologous collagen albumen；
Step 2: the preparation of autologous fat stem cell
(1) fat stem cell separates: obtaining the autologous adipose tissue for being located at abdomen, physiological saline, mixing, with revolving speed is added
1200r/min is centrifuged 20min, removes remaining haemocyte and fragment of tissue, obtains adipose tissue, presses body to the adipose tissue
The Type I collagen enzyme solutions that mass concentration is 0.1% are added than 1:2 for product, 30min are digested in 37 DEG C of waters bath with thermostatic control, with revolving speed
1500r/min is centrifuged 2min, discards upper-layer fat tissue and lower layer's suspension, obtains fat stem cell precipitating；
(2) fat stem cell culture: being added DMEM culture medium for the fat stem cell of acquisition precipitating and be resuspended, be placed in 37 DEG C,
5%CO2Culture, passage, when the degrees of fusion of the fat mesenchymal stem cell is up to 80% or more, are collected thin until the 3rd generation terminated
Born of the same parents use or freeze；
Step 3: production preparation
Weight percentage, by autologous collagen albumen 55%, autologous fat stem cell 20%, epidermal growth factor
20%, two contracting glycerin ether 5% of polyethylene glycol is uniformly mixed, preparation is made, is placed in 4 DEG C of Preservation in sterile condition.
Embodiment 3
A kind of injection based on autologous tissue, preparation method include:
Step 1: the preparation of autologous collagen albumen
By blood taking needle, to human body, blood was collected, and blood enters whole blood separator after being centrifuged for the first time, and separates in whole blood
Secondary centrifuging is carried out in device, whole blood centrifugation is divided into three layers, plasma layer, tunica albuginea layer and red blood cell layer is followed successively by from top to bottom, by blood
The liquid of pulp layer, tunica albuginea layer and red blood cell layer, which passes through conduit respectively and imports different storage elements, separately to be stored, by storage element
It takes out appropriate plasma layer and tunica albuginea layer liquid is mixed by 1:1, and is further pure through chromatography unit progress preliminary purification, diafiltration unit
Change up to required autologous collagen albumen；
Step 2: the preparation of autologous fat stem cell
(1) fat stem cell separates: obtaining the autologous adipose tissue for being located at abdomen, physiological saline, mixing, with revolving speed is added
1200r/min is centrifuged 18min, removes remaining haemocyte and fragment of tissue, obtains adipose tissue, presses body to the adipose tissue
The Type I collagen enzyme solutions that mass concentration is 0.075% are added than 1:3 for product, 45min are digested in 37 DEG C of waters bath with thermostatic control, with revolving speed
1200r/min is centrifuged 6min, discards upper-layer fat tissue and lower layer's suspension, obtains fat stem cell precipitating；
(2) fat stem cell culture: being added DMEM culture medium for the fat stem cell of acquisition precipitating and be resuspended, be placed in 37 DEG C,
5%CO2Culture, passage, when the degrees of fusion of the fat mesenchymal stem cell is up to 80% or more, are collected thin until the 3rd generation terminated
Born of the same parents use or freeze；
Step 3: production preparation
Weight percentage, by autologous collagen protein 60 %, autologous fat stem cell 20%, epidermal growth factor
17%, 1,4- butanediol glycidol ether 3% are uniformly mixed, preparation are made, is placed in 4 DEG C of Preservation in sterile condition.
Embodiment 4
A kind of injection based on autologous tissue, preparation method include:
Step 1: the preparation of autologous collagen albumen
By blood taking needle, to human body, blood was collected, and blood enters whole blood separator after being centrifuged for the first time, and separates in whole blood
Secondary centrifuging is carried out in device, whole blood centrifugation is divided into three layers, plasma layer, tunica albuginea layer and red blood cell layer is followed successively by from top to bottom, by blood
The liquid of pulp layer, tunica albuginea layer and red blood cell layer, which passes through conduit respectively and imports different storage elements, separately to be stored, by storage element
It takes out appropriate plasma layer and tunica albuginea layer liquid is mixed by 1:1, and is further pure through chromatography unit progress preliminary purification, diafiltration unit
Change up to required autologous collagen albumen；
Step 2: the preparation of autologous fat stem cell
(1) fat stem cell separates: obtaining the autologous adipose tissue for being located at abdomen, physiological saline, mixing, with revolving speed is added
1200r/min is centrifuged 20min, removes remaining haemocyte and fragment of tissue, obtains adipose tissue, presses body to the adipose tissue
The Type I collagen enzyme solutions that mass concentration is 0.09% are added than 1:2 for product, 35min are digested in 37 DEG C of waters bath with thermostatic control, with revolving speed
1200r/min is centrifuged 3min, discards upper-layer fat tissue and lower layer's suspension, obtains fat stem cell precipitating；
(2) fat stem cell culture: being added DMEM culture medium for the fat stem cell of acquisition precipitating and be resuspended, be placed in 37 DEG C,
5%CO2Culture, passage, when the degrees of fusion of the fat mesenchymal stem cell is up to 80% or more, are collected thin until the 3rd generation terminated
Born of the same parents use or freeze；
Step 3: production preparation
Weight percentage, by autologous collagen protein 70 %, autologous fat stem cell 10%, insulin-like growth because
Sub 12%, two contracting glycerin ether 8% of polyethylene glycol, are uniformly mixed, preparation are made, is placed in 4 DEG C of Preservation in sterile condition.
Embodiment 5
A kind of injection based on autologous tissue, preparation method include:
Step 1: the preparation of autologous collagen albumen
By blood taking needle, to human body, blood was collected, and blood enters whole blood separator after being centrifuged for the first time, and separates in whole blood
Secondary centrifuging is carried out in device, whole blood centrifugation is divided into three layers, plasma layer, tunica albuginea layer and red blood cell layer is followed successively by from top to bottom, by blood
The liquid of pulp layer, tunica albuginea layer and red blood cell layer, which passes through conduit respectively and imports different storage elements, separately to be stored, by storage element
It takes out appropriate plasma layer and tunica albuginea layer liquid is mixed by 1:1, and is further pure through chromatography unit progress preliminary purification, diafiltration unit
Change up to required autologous collagen albumen；
Step 2: the preparation of autologous fat stem cell
(1) fat stem cell separates: obtaining the autologous adipose tissue for being located at abdomen, physiological saline, mixing, with revolving speed is added
1500r/min is centrifuged 20min, removes remaining haemocyte and fragment of tissue, obtains adipose tissue, presses body to the adipose tissue
The Type I collagen enzyme solutions that mass concentration is 0.1% are added than 1:2 for product, 30min are digested in 37 DEG C of waters bath with thermostatic control, with revolving speed
1000r/min is centrifuged 6min, discards upper-layer fat tissue and lower layer's suspension, obtains fat stem cell precipitating；
(2) fat stem cell culture: being added DMEM culture medium for the fat stem cell of acquisition precipitating and be resuspended, be placed in 37 DEG C,
5%CO2Culture, passage, when the degrees of fusion of the fat mesenchymal stem cell is up to 80% or more, are collected thin until the 3rd generation terminated
Born of the same parents use or freeze；
Step 3: production preparation
Weight percentage, by autologous collagen albumen 50%, autologous fat stem cell 30%, fibroblastic growth
The factor 10%, 1,4- butanediol glycidol ether 10% are uniformly mixed, preparation are made, is placed in 4 DEG C of Preservation in sterile condition.
Test case
There is good chest enlarge effect in order to illustrate the preparation of the invention made of autologous tissue, under the present invention has carried out
Column clinical trial.
1, general information
It chooses 2 months -2017 years 2 months 2015 and voluntarily receives enlarge the bosom 60 women as research object, year in mechanism
It age 20-45 years old, is in a good state of health, no other systems disease signs informed consent form before enlarging the bosom.It is included in standard: 1. former
Hair property micromazia, chest are flat.2. the spontaneous mammary atrophy after gestation.3. breast tissue lesion or post-traumatic cream
Room depauperation.4. breast is anisopleual or has slight sagging person.5. being included in the experiment of patient's voluntary participation, and signs and know together
Meaning book.Exclusion criteria: 1. psychological preparation deficiency person.2. breast tissue has inflammation or the operative incision person that nearby has scytitis.③
With schizophrenia or insanity person.4. the important organs such as the heart, liver, kidney have lesion person.5. suffering from immune system or hematopoiesis
Systemic disease person.6. mastocarcinoma postoperative recurrence or the person that has metastasis tendency.The patient that will enlarge the bosom is randomly divided into test 1-5 group and control
Group, each group is 10 people, and two groups of patient's comparing differences in general information are unobvious, do not have statistical significance (P >
0.05)。
2, treatment method
Test group: test group 1-5 uses injection made from 1-5 of the embodiment of the present invention respectively.It incite somebody to action this by design injection point
Injection made from inventive embodiments is injected according to hypodermic layer, mammary gland lower layer Multiple tunnel multiple spot, and after having injected, massage makes rouge
Fat is evenly distributed.
Control group: autologous fat obtained is carried out according to hypodermic layer, mammary gland lower layer Multiple tunnel multiple spot by design injection point
Injection, after having injected, massage keeps Fat Distribution uniform.
3, curative effect determinate standard
Effective: position, size are symmetrically harmonious under different positions；Feel is natural, dynamic true to nature；It is quick of perception.
Effective: position, size are symmetrically harmonious under vertical position；Position, the symmetrical concordance of size are slightly worse when clinostatism；Feel nature,
It is dynamic slightly worse；It is quick of perception.
Invalid: position, size symmetry are poor under various positions；Feel is unnatural, dynamic difference；Feel insensitive.
4, result
Follow-up After 3-6 months, the therapeutic effect comparing result of the two was shown in Table 1.
Table 1
| Group | It is effective | Effectively | In vain | Total effective rate |
| Test group 1 | 8 | 1 | 1 | 90% |
| Test group 2 | 7 | 2 | 1 | 90% |
| Test group 3 | 7 | 3 | 0 | 100% |
| Test group 4 | 8 | 1 | 1 | 90% |
| Test group 5 | 8 | 2 | 0 | 100% |
| Control group | 2 | 4 | 4 | 60% |
The result shows that: the total effective rate of test group 1-5 reaches 90% or more, hence it is evident that better than the total effective rate of control group
60%, difference has statistical significance.The embodiment of the present invention can effectively inhibit the absorption, infection, necrosis of transplant fat, promote
The revascularization of transplant fat tissue, transplant fat high survival rate, mammoplasia effect are good.
Although above having used general explanation and specific embodiment, the present invention is described in detail, at this
On the basis of invention, it can be made some modifications or improvements, this will be apparent to those skilled in the art.Therefore,
These modifications or improvements without departing from theon the basis of the spirit of the present invention are fallen within the scope of the claimed invention.
Claims (8)
1. a kind of preparation based on autologous tissue, which is characterized in that the preparation includes that autologous collagen albumen and autologous fat are dry
Cell.
2. the preparation according to claim 1 based on autologous tissue, which is characterized in that the preparation is injection, system
Preparation Method includes:
Step 1: the preparation of autologous collagen albumen
By blood taking needle, to human body, blood was collected, and blood enters whole blood separator after being centrifuged for the first time, and in whole blood separator
Carry out secondary centrifuging, whole blood centrifugation is divided into three layers, be followed successively by plasma layer, tunica albuginea layer and red blood cell layer from top to bottom, by plasma layer,
The liquid of tunica albuginea layer and red blood cell layer, which passes through conduit respectively and imports different storage elements, separately to be stored, and is taken out by storage element suitable
Plasma layer and the mixing of tunica albuginea layer liquid proportional are measured, and is further purified i.e. through chromatography unit progress preliminary purification, diafiltration unit
Obtain required autologous collagen albumen；
Step 2: the preparation of autologous fat stem cell
(1) fat stem cell separates: obtaining the autologous adipose tissue for being located at abdomen, physiological saline, mixing, with revolving speed is added
1200-1800r/min is centrifuged 10-20min, removes remaining haemocyte and fragment of tissue, adipose tissue is obtained, to the fat
The Type I collagen enzyme solutions that mass concentration is 0.075-0.1% are added in 1:2-3 to tissue by volume, digest in 37 DEG C of waters bath with thermostatic control
30-60min is centrifuged 2-6min with revolving speed 1000-1500r/min, discards upper-layer fat tissue and lower layer's suspension, it is dry to obtain fat
Cell precipitation；
(2) fat stem cell culture: DMEM culture medium is added in the fat stem cell precipitating of acquisition and is resuspended, 37 DEG C, 5%CO are placed in2
Culture, passage, when the degrees of fusion of the fat mesenchymal stem cell is up to 80% or more, is collected cell and are used until the 3rd generation terminated
Or it freezes；
Step 3: production preparation
By autologous fat stem cell made from autologous collagen albumen made from step 1 and step 2, it is uniformly mixed, is placed in 4 DEG C of nothings
Bacterium saves.
3. the preparation according to claim 1 based on autologous tissue, which is characterized in that the preparation further includes promoting cell
The Porcine HGF of growth, according to weight, the preparation includes autologous collagen albumen 50-80%, from body fat
Fat stem cell 20-50%, the cell growth factor 10-30% for promoting cell growth.
4. the preparation according to claim 3 based on autologous tissue, which is characterized in that the Porcine HGF includes into
One of fibroblast growth factor, epidermal growth factor, insulin-like growth factor are a variety of.
5. the preparation according to claim 3 based on autologous tissue, which is characterized in that the preparation further includes weight percent
Content is the crosslinking agent of 1-20%.
6. the preparation according to claim 5 based on autologous tissue, which is characterized in that the crosslinking agent is selected from 1,4- fourth two
One or both of alcohol glycidol ether, two contracting glycerin ether of polyethylene glycol.
7. one kind is described in claim 1 to prepare the application in soft tissue filler based on the preparation of autologous tissue.
8. application according to claim 7, which is characterized in that the soft tissue is chest soft tissue.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110960706.2A CN113456807A (en) | 2018-08-27 | 2018-08-27 | Soft tissue filler and application thereof |
| CN201810978453.XA CN109078172A (en) | 2018-08-27 | 2018-08-27 | A kind of preparation and its application based on autologous tissue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810978453.XA CN109078172A (en) | 2018-08-27 | 2018-08-27 | A kind of preparation and its application based on autologous tissue |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110960706.2A Division CN113456807A (en) | 2018-08-27 | 2018-08-27 | Soft tissue filler and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109078172A true CN109078172A (en) | 2018-12-25 |
Family
ID=64794746
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110960706.2A Withdrawn CN113456807A (en) | 2018-08-27 | 2018-08-27 | Soft tissue filler and application thereof |
| CN201810978453.XA Pending CN109078172A (en) | 2018-08-27 | 2018-08-27 | A kind of preparation and its application based on autologous tissue |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110960706.2A Withdrawn CN113456807A (en) | 2018-08-27 | 2018-08-27 | Soft tissue filler and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN113456807A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109876195A (en) * | 2019-02-22 | 2019-06-14 | 王亚楠 | A kind of preparation method of the filling material of bone of inducible rapid bone formation |
| CN111110623A (en) * | 2019-06-28 | 2020-05-08 | 青岛华澳现代医疗美容有限公司 | Self-repairing small needle nutrient solution formula |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101850132A (en) * | 2009-03-31 | 2010-10-06 | 中山大学附属第一医院 | Tissue engineered breast transplant and constructing method thereof |
| CN101979410A (en) * | 2010-11-09 | 2011-02-23 | 白晋 | Equipment for preparing collagen |
| CN102258810A (en) * | 2011-07-20 | 2011-11-30 | 王泰华 | Preparation method of adipose tissue breast augmentation material enriched with autologous stem cells |
| CN108341865A (en) * | 2018-05-18 | 2018-07-31 | 白晋 | A kind of novel equipment and method for preparing collagen |
-
2018
- 2018-08-27 CN CN202110960706.2A patent/CN113456807A/en not_active Withdrawn
- 2018-08-27 CN CN201810978453.XA patent/CN109078172A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101850132A (en) * | 2009-03-31 | 2010-10-06 | 中山大学附属第一医院 | Tissue engineered breast transplant and constructing method thereof |
| CN101979410A (en) * | 2010-11-09 | 2011-02-23 | 白晋 | Equipment for preparing collagen |
| CN102258810A (en) * | 2011-07-20 | 2011-11-30 | 王泰华 | Preparation method of adipose tissue breast augmentation material enriched with autologous stem cells |
| CN108341865A (en) * | 2018-05-18 | 2018-07-31 | 白晋 | A kind of novel equipment and method for preparing collagen |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109876195A (en) * | 2019-02-22 | 2019-06-14 | 王亚楠 | A kind of preparation method of the filling material of bone of inducible rapid bone formation |
| CN109876195B (en) * | 2019-02-22 | 2021-12-10 | 王亚楠 | Preparation method of bone filling material capable of inducing rapid bone formation |
| CN111110623A (en) * | 2019-06-28 | 2020-05-08 | 青岛华澳现代医疗美容有限公司 | Self-repairing small needle nutrient solution formula |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113456807A (en) | 2021-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103071191A (en) | Preparation method of autologous platelet-factor-rich plasma (PFRP) preparation | |
| CN111110623A (en) | Self-repairing small needle nutrient solution formula | |
| CN108938448A (en) | A kind of RF beauty autologous collagen protein liquid and its application method | |
| CN108686255A (en) | It is a kind of to prevent the biological dressing and preparation method thereof that scar is formed | |
| CN106420390A (en) | Stem cell preparation for skin beauty and preparation method thereof | |
| CN106110389A (en) | A kind of moist dressing of skin wound and its preparation method and application | |
| CN108543064A (en) | A kind of quick reparation liquid and preparation method thereof for burn and scald | |
| CN104056258A (en) | Composition for promoting physiologically regulative regeneration of damaged tissue as well as preparation method and use thereof | |
| CN108653790A (en) | A kind of biological dressing of prevention and reduction scar formation | |
| CN109865033A (en) | A kind of external application medical ointment and its application in reparation diabetes wound | |
| CN109078172A (en) | A kind of preparation and its application based on autologous tissue | |
| CN108743921A (en) | It is a kind of to prevent the reparation liquid and its preparation method and application that scar is formed | |
| CN109700998A (en) | A kind of compound skin injury regeneration renovation agent and preparation method thereof | |
| CN105597088A (en) | Preparation and preparation method and application thereof | |
| CN101088569A (en) | Human skin filler for injection and its prepn process | |
| CN111117955A (en) | Method for improving breast adipose cell survival rate by using autologous adipose-derived stem cells | |
| Matthews-Brzozowska et al. | Revitalization of facial skin based on preparations of patient own blood | |
| CN111110832A (en) | A preparation containing snail extractive solution and Chinese Holly extract for treating wound and scar, and its preparation method | |
| CN108671268A (en) | A kind of fat injection agent and preparation method for injecting beauty | |
| CN101804071A (en) | Injection for treating skin defect and preparation method thereof | |
| CN102357263A (en) | Composite inducer for promoting autologous peripheral preadipocyte proliferation and enlargement for cosmesis and body beautification and preparation method thereof | |
| CN111973806A (en) | Composition and application thereof | |
| CN108096624A (en) | Preparation method, material and the application of cell scaffold material | |
| CN108392669A (en) | A kind of bioactive polysaccharide dressing and its preparation method and application for wound repair | |
| CN115025121B (en) | Composite cell preparation and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181225 |